Nevro (NVRO) Stock Forecast & Price Target

$4.07 -0.38 (-8.55%)

(As of 11/14/2024 ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 14 Analyst Ratings

Sell
3

Hold
11

Buy
0

Based on 14 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 14 analysts, 3 have given a sell rating, and 11 have given a hold rating for NVRO.

Consensus Price Target

$9.10
123.86% Upside

According to the 14 analysts' twelve-month price targets for Nevro, the average price target is $9.10. The highest price target for NVRO is $23.00, while the lowest price target for NVRO is $5.50. The average price target represents a forecasted upside of 123.86% from the current price of $4.07.

NVRO Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	4 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	11 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$9.10	$10.55	$10.63	$27.50
Forecasted Upside	123.86% Upside	107.59% Upside	90.10% Upside	62.63% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Nevro Stock vs. The Competition

Type	Nevro	Medical Companies	S&P 500
Consensus Rating Score	1.79	2.80	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	123.59% Upside	26,227.44% Upside	8.88% Upside
News Sentiment Rating	Neutral News See Recent NVRO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	JMP Securities 2 of 5 stars	D. Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
11/12/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Hold ➝ Hold	$8.00 ➝ $7.00	+13.27%
11/12/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Sector Perform ➝ Sector Perform	$7.00 ➝ $7.00	+10.41%
11/12/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$7.00 ➝ $6.00	+12.57%
11/12/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$5.00 ➝ $6.00	+12.57%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$6.89 ➝ $6.00	+13.64%
Financial Prophecy (Ad) The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy.
8/8/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$10.00 ➝ $5.50	+13.17%
8/8/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Treybeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$13.00 ➝ $5.50	-36.71%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $9.00	-4.26%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$20.00 ➝ $16.00	+20.30%
2/22/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:27 AM ET.

NVRO Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $9.10, with a high forecast of $23.00 and a low forecast of $5.50.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings and 11 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NVRO shares.
: According to analysts, Nevro's stock has a predicted upside of 123.86% based on their 12-month stock forecasts.
: Nevro has been rated by research analysts at Canaccord Genuity Group, Citigroup, JMP Securities, Piper Sandler, Robert W. Baird, and Royal Bank of Canada in the past 90 days.
: Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

This page (NYSE:NVRO) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nevro (NVRO) Stock Forecast & Price Target